Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

104.28 +0.43 (+0.41%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
42 43 Next >
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
Exposures COVID-19
New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting
Via Benzinga
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
Via Benzinga
Novartis: Q1 Earnings Insights
Novartis (NYSE:NVS) reported its Q1 earnings results on Tuesday, April 26, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
6 Dividend Stocks With High Yields and Low P/E Ratios
These 6 dividend stocks have yields greater than 2.5% and P/E ratios lower than 16x with a positive earnings growth forecast for 2023. 
Via InvestorPlace
Online shop Etalaze announces shift to a new domain www.Etalaze.biz
Via AB Newswire
Analyzing Novartis's Short Interest
Novartis's (NYSE:NVS) short percent of float has risen 3.57% since its last report. The company recently reported that it has 6.56 million shares sold short, which is 0.29% of all... 
Via Benzinga
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach... 
Via iCrowdNewswire
Current Report: Novartis (NVS)
Novartis’s price per share was $87.81 as of yesterday's market close. One year ago its price was $88.85. 
Via Talk Markets
Here's The Surprising Source Of Novartis' First-Quarter Sales Growth
An unexpected business contributed 8% to Novartis' first-quarter sales growth. 
Via Investor's Business Daily
Earnings Scheduled For April 26, 2022
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million. 
Via Benzinga
Asia-Pacific Anti-Inflammatory Therapeutics Market Qualitative Insights on Application & Outlook by Share, Future Growth
Asia-Pacific Anti-Inflammatory Therapeutics Market Qualitative Insights on Application & Outlook by Share, Future Growth Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR... 
Via iCrowdNewswire
Topics Intellectual Property
Exposures Intellectual Property
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
3 Undervalued Stocks to Buy Before You Sell in May and Go Away
If you really decide to sell in May and go away, you may miss out some profits from these undervalued stocks to buy. 
Via InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped. 
Via Investor's Business Daily
Surgical Equipment Market Top Companies, Business Growth & Investment Opportunities, Share
Surgical Equipment Market Top Companies, Business Growth & Investment Opportunities, Share The global surgical equipment market valued at $31,722.30 million in 2019 and is estimated to reach $44,448.58... 
Via iCrowdNewswire
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Setareh Williams Joins Cobbs Creek Healthcare as Managing Partner/Head of Real-World Evidence and Scientific Communications
Cobbs Creek Healthcare Expanding Into RWE/HEOR Area 
Via Newswire.com
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Rancho Biosciences Launches the Single Cell Data Science Consortium With Four Charter Members
Rancho Biosciences, a leading company in the field of data curation and data services, is pleased to announce the launch of its Single Cell Data Science (SCDS) pre-competitive consortium. The... 
Via Newswire.com
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data
Via Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook
Via Benzinga
Novartis Earnings Preview
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Novartis will report... 
Via Benzinga
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
Via Benzinga
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.